AstraZeneca PLC (AZN.L)
AZN.L on London Stock Exchange
6,159.00GBp
22 Feb 2019
6,159.00GBp
22 Feb 2019
Change (% chg)
63.00 (+1.03%)
63.00 (+1.03%)
Prev Close
6,096.00
6,096.00
Open
6,100.00
6,100.00
Day's High
6,197.00
6,197.00
Day's Low
6,081.00
6,081.00
Volume
1,724,090
1,724,090
Avg. Vol
2,079,667
2,079,667
52-wk High
6,432.48
6,432.48
52-wk Low
4,710.50
4,710.50
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | 0.82 | December | 22 Feb 2019 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 7 | 7 | 7 | 8 |
| (2) OUTPERFORM | 11 | 9 | 9 | 9 |
| (3) HOLD | 6 | 9 | 9 | 8 |
| (4) UNDERPERFORM | 2 | 2 | 2 | 3 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.12 | 2.22 | 2.22 | 2.21 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Mar-19 | 6 | 5,443.46 | 5,692.76 | 5,236.00 | 5,531.36 |
| Quarter Ending Jun-19 | 6 | 5,578.02 | 5,657.70 | 5,485.00 | 5,337.68 |
| Year Ending Dec-19 | 26 | 23,492.90 | 24,671.00 | 22,162.00 | 23,847.80 |
| Year Ending Dec-20 | 24 | 25,861.10 | 29,030.00 | 23,698.40 | 25,961.40 |
| Earnings (per share) | |||||
| Quarter Ending Mar-19 | 5 | 0.82 | 0.97 | 0.69 | 1.01 |
| Quarter Ending Jun-19 | 4 | 0.76 | 0.88 | 0.65 | 0.95 |
| Year Ending Dec-19 | 27 | 3.65 | 4.16 | 3.00 | 3.98 |
| Year Ending Dec-20 | 24 | 4.48 | 5.54 | 3.61 | 4.71 |
| LT Growth Rate (%) | 3 | 10.25 | 13.80 | 3.75 | 4.43 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Dec-18 | 6,385.64 | 6,417.00 | 31.36 | 0.49 |
| Quarter Ending Sep-18 | 5,302.97 | 5,340.00 | 37.03 | 0.70 |
| Quarter Ending Jun-18 | 4,822.20 | 5,155.00 | 332.80 | 6.90 |
| Quarter Ending Mar-18 | 5,282.61 | 5,178.00 | 104.61 | 1.98 |
| Quarter Ending Dec-17 | 5,473.40 | 5,777.00 | 303.60 | 5.55 |
| Earnings (per share) | ||||
| Quarter Ending Dec-18 | 1.43 | 1.58 | 0.15 | 10.14 |
| Quarter Ending Sep-18 | 0.70 | 0.71 | 0.01 | 1.00 |
| Quarter Ending Jun-18 | 0.71 | 0.69 | 0.02 | 2.69 |
| Quarter Ending Mar-18 | 0.60 | 0.48 | 0.12 | 20.19 |
| Quarter Ending Dec-17 | 0.84 | 1.30 | 0.46 | 54.91 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Mar-19 | 5,443.46 | 5,388.57 | 5,380.84 | 5,444.51 | 5,531.36 |
| Quarter Ending Jun-19 | 5,578.02 | 5,510.78 | 5,575.04 | 5,620.70 | 5,337.68 |
| Year Ending Dec-19 | 23,492.90 | 23,382.90 | 23,441.60 | 23,549.90 | 23,847.80 |
| Year Ending Dec-20 | 25,861.10 | 25,764.30 | 25,798.80 | 25,933.90 | 25,961.40 |
| Earnings (per share) | |||||
| Quarter Ending Mar-19 | 0.82 | 0.81 | 0.84 | 0.84 | 1.01 |
| Quarter Ending Jun-19 | 0.76 | 0.72 | 0.73 | 0.73 | 0.95 |
| Year Ending Dec-19 | 3.65 | 3.64 | 3.72 | 3.83 | 3.98 |
| Year Ending Dec-20 | 4.48 | 4.51 | 4.57 | 4.63 | 4.71 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Mar-19 | 2 | 0 | 0 | 2 |
| Quarter Ending Jun-19 | 2 | 0 | 0 | 2 |
| Year Ending Dec-19 | 7 | 4 | 8 | 8 |
| Year Ending Dec-20 | 6 | 4 | 8 | 7 |
| Earnings | ||||
| Quarter Ending Mar-19 | 2 | 0 | 1 | 1 |
| Quarter Ending Jun-19 | 2 | 0 | 1 | 1 |
| Year Ending Dec-19 | 6 | 5 | 6 | 10 |
| Year Ending Dec-20 | 3 | 6 | 3 | 11 |
Earnings vs. 
Estimates- UPDATE 2-HSBC, stronger pound pressure FTSE 100; Greggs outshines mid-caps
- UPDATE 2-FTSE 100 dips as investors book in profits, pound strengthens; Reckitt shines
- FTSE 100 squeezes out gains; ConvaTec drags midcaps
- GLOBAL MARKETS-Fall in U.S. retail sales dampens world stock market rally
- GLOBAL MARKETS-Fall in U.S. retail sales dampens world stock market rally
- What does AstraZeneca plc's deal with Pfizer mean for shareholders?
- Is Hikma Pharmaceuticals plc the best FTSE 100 healthcare stock to own after today’s update?
- 3 stocks to help you retire early
- Is it time to take profits on GlaxoSmithKline plc and AstraZeneca plc?
- These FTSE 100 stars have exploded in Q3! And they're not finished yet
- Why now is the perfect time to buy these 3 super income stocks